SomaLogic stock (US82489T1043): merger with Standard BioTools reshapes proteomics player
SomaLogic has completed an all-stock merger with Standard BioTools, creating a new life-science tools group focused on proteomics and genomics. This strategic move aims to diversify their offerings, enhance scale, and reduce costs. The combined entity seeks to leverage its expanded platform to drive growth in the multi-omics market while navigating integration challenges and competitive pressures.
SomaLogic Inc stock (US82489T1043): Illumina merger closes and reshapes proteomics story
SomaLogic Inc has completed its all-stock merger with Standard BioTools, forming a combined life-science tools company focused on proteomics and multi-omics. This strategic move aims to accelerate advanced proteomics adoption, create cost synergies, and broaden their product portfolio for academic research, biopharma, and diagnostics development. The new entity will operate under the Standard BioTools name, with former SomaLogic shareholders holding a significant minority stake.
MAK Capital (NASDAQ: LAB) reports 6.7% stake in Standard BioTools
MAK Capital and related entities have reported a 6.7% passive stake in Standard BioTools Inc. (NASDAQ: LAB) through a Schedule 13G/A SEC filing. This ownership amounts to 26,172,626 shares, with shared voting and dispositive power, calculated as of May 15, 2026, against 390,368,119 shares outstanding. The filing indicates a neutral impact and sentiment, with no immediate transactional activity or board engagement disclosed.
Viking Global (LAB) holds 58.65M shares (~15%) of Standard BioTools
Viking Global Investors and its affiliated entities have reported a beneficial ownership of 58.65 million shares, representing a 15.0% stake in Standard BioTools (LAB). This disclosure was made via an amended Schedule 13G/A filing with the SEC, specifying the holdings are split between Viking Global Opportunities (VGOP) and Viking Global Opportunities Drawdown (VGOD). The filing also noted the removal of David C. Ott as a reporting person due to his retirement.
Standard Biotools Faces Nasdaq Delisting Risk After Prolonged Sub-$1 Share Price
Standard Biotools Inc. (LAB) is at risk of delisting from Nasdaq because its share price has traded below the $1.00 minimum bid for 30 consecutive business days. The company received a deficiency notice on April 20, 2026, and must regain compliance by October 19, 2026, to avoid potential delisting. Delisting could negatively impact share liquidity and the company's ability to raise capital.
Number of shareholders of Standard BioTools Inc. – NASDAQ:LAB
This article provides the number of shareholders for Standard BioTools Inc. (NASDAQ: LAB). It indicates that the market is currently closed with no trades. The data is presented within the context of TradingView's platform, highlighting its financial and market analysis features.
Standard BioTools (LAB) Premium P/S Multiple Tests Narratives After Another Quarterly Loss
Standard BioTools (LAB) reported Q1 2026 revenue of US$21.1 million and an EPS loss of US$0.04, continuing a trend of quarterly losses. The company's trailing 12-month revenue growth was a modest 0.9%, below market benchmarks, and it maintains a premium Price/Sales (P/S) multiple of 4.4x despite ongoing unprofitability. This performance raises questions about its valuation and ability to achieve profitability and significant revenue growth as predicted by some narratives.
Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry
Molecular Instruments (MI) and Standard BioTools Inc. have announced a collaboration to integrate MI's HCR™ signal amplification technology with Standard BioTools' Imaging Mass Cytometry™ (IMC™). This partnership aims to significantly enhance multi-omic spatial analysis by enabling high-sensitivity, high-plex detection of a wide array of biomarkers, including RNA and protein, at subcellular resolution. The collaboration will initially focus on developing and validating HCR-amplified multi-omic workflows for the Hyperion™ Imaging System and will include joint marketing and sales efforts.
Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry
Molecular Instruments (MI) and Standard BioTools Inc. (Nasdaq: LAB) have announced a collaboration to combine MI's programmable in situ amplification technology with Standard BioTools' Imaging Mass Cytometry platform. This partnership aims to enable highly multiplexed, ultra-sensitive, and quantitative spatial analysis of RNA and protein in biological samples. The integration is expected to offer researchers unprecedented insights into cellular function and tissue microenvironments.
Standard BioTools 1Q Loss/Shr 4c >LAB
Standard BioTools announced a first-quarter loss per share of 4 cents. This financial update indicates the company's performance for the most recent quarter.
Standard BioTools: Q1 Earnings Snapshot
Standard BioTools Inc. (LAB) announced its Q1 earnings, reporting a net income of $127.1 million. The company posted a profit of 33 cents per share and adjusted losses of 2 cents per share, with revenue for the period reaching $21.1 million.
Standard BioTools: Q1 Earnings Snapshot
Standard BioTools Inc. (LAB) announced its first-quarter earnings, reporting a net income of $127.1 million, which translates to a profit of 33 cents per share. After adjusting for one-time costs, the company experienced a loss of 2 cents per share. The Boston-based manufacturer of fluid control equipment also reported revenues of $21.1 million for the period.
Standard BioTools (LAB) Q1 2026 results show big cash boost and EBITDA gains
Standard BioTools (LAB) reported strong Q1 2026 results, with revenue up 5% to $21.1 million and a significant 78% improvement in adjusted EBITDA loss to $3.1 million. The company's cash and liquid investments surged to $523.6 million, largely due to the $363.2 million from the SomaLogic sale, providing substantial financial flexibility. Despite a decline in instrument revenue due to capital-constrained markets, robust consumables growth and effective restructuring efforts underscore a positive trajectory towards profitability, with full-year revenue projected between $80-$85 million.
Standard BioTools ends quarter with $524M as loss shrinks 54%
Standard BioTools (NASDAQ: LAB) reported a 5% year-over-year revenue increase to $21.1 million for Q1 2026, with a significant 78% improvement in adjusted EBITDA, resulting in a loss of $3.1 million. The company ended the quarter with $523.6 million in cash and investments and reiterated its full-year 2026 revenue guidance of $80–$85 million, emphasizing strategic capital deployment and cost-saving initiatives. Consumables revenue saw a 35% growth, while instrument revenue declined by 33% due to capital-constrained markets.
Standard BioTools Reports First Quarter 2026 Financial Results
Standard BioTools Inc. announced strong first-quarter 2026 financial results, exceeding expectations with $21.1 million in revenue and significant improvements in operating loss and adjusted EBITDA, primarily due to cost savings initiatives. The company reported a substantial cash and investments balance of $524 million, bolstering its inorganic growth strategy. With the sale of SomaLogic complete, Standard BioTools is now focused on strategic capital deployment and maintaining its full-year 2026 revenue outlook of $80 million to $85 million.
Standard BioTools: Q1 Earnings Snapshot
Standard BioTools Inc. reported net income of $127.1 million for its first quarter, translating to a profit of 33 cents per share. After adjusting for one-time factors, the company experienced a loss of 2 cents per share. The equipment manufacturer also posted revenues of $21.1 million for the period.
Standard BioTools Inc expected to post a loss of 6 cents a share - Earnings Preview
Standard BioTools Inc (LAB) is projected to report a loss of 6 cents per share, according to a recent earnings preview. This forecast is based on information from Refinitiv, indicating an anticipated financial performance for the company.
Standard BioTools (LAB) Projected to Post Earnings on Tuesday
Standard BioTools (NASDAQ:LAB) is projected to report its Q1 2026 earnings on Tuesday, May 5th, with analysts forecasting an EPS of ($0.02) and revenue of $17.8 million. The company's previous quarter showed a beat on both EPS and revenue expectations but continues to struggle with negative profitability metrics. Analyst sentiment remains cautious with a "Reduce" rating and a target price of $1.35, despite increased institutional ownership.
Standard BioTools (NASDAQ: LAB) details 2026 votes and Illumina deal cash boost
Standard BioTools (NASDAQ: LAB) has published details for its 2026 annual stockholder meeting, scheduled virtually for June 17, 2026. Key proposals include the election of three Class I directors, an advisory "say-on-pay" vote for executive compensation, ratification of PwC as the independent auditor, approval of a new 2026 Equity Incentive Plan, and an amendment to increase shares under the 2017 Employee Stock Purchase Plan. The company highlighted its strong financial position after divesting SomaLogic and related units to Illumina for up to $425 million plus royalties, resulting in approximately $550 million in cash and investments post-transaction in January 2026.
[ARS] STANDARD BIOTOOLS INC. SEC Filing
This article announces an ARS SEC filing by STANDARD BIOTOOLS INC. (LAB) on April 27, 2026, at 04:20 PM UTC. The filing is available as a PDF document directly from the SEC EDGAR source. The article also provides a brief overview of LAB's stock data, rankings, and recent news and SEC filings.
Standard BioTools Receives Nasdaq Minimum Bid Price Deficiency Notice
Standard BioTools (LAB) has received a Nasdaq deficiency notice because its shares have fallen below the $1.00 minimum bid price for 30 consecutive business days. The company has 180 days, until October 19, 2026, to regain compliance by achieving a minimum bid price of at least $1.00 for 10 consecutive business days, potentially through measures like a reverse stock split. Failure to do so could result in delisting, though an additional 180-day period might be available if it transfers to the Nasdaq Capital Market.
Nasdaq warns Standard BioTools (NASDAQ: LAB) on sub-$1.00 bid price
Standard BioTools Inc. (NASDAQ: LAB) has received a notice from Nasdaq for failing to meet the $1.00 minimum bid price requirement for 30 consecutive business days. The company has 180 calendar days, until October 19, 2026, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days. Potential remedies include a reverse stock split, and while the company intends to comply, there's no guarantee of success or an extension.
Standard BioTools Disclosed Failure to Satisfy a Continued Listing Rule or Standard
Standard BioTools (LAB) has received a Nasdaq notice for failing to meet the minimum $1.00 bid price for 30 consecutive business days. The company has until October 19, 2026, to regain compliance, with a possible extension if it transfers to the Nasdaq Capital Market. Trading of LAB continues on the Nasdaq Global Select Market.
Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
Standard BioTools Inc. (NASDAQ: LAB) announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, after the U.S. market closes. The company, a leading provider of next-generation technologies for biomedical research, uses proprietary mass cytometry and microfluidics to deliver insights in health and disease. Standard BioTools collaborates with academic, government, pharmaceutical, and biotechnology laboratories globally, focusing on translational and clinical research in areas like oncology and immunology.
Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
Standard BioTools Inc. (NASDAQ: LAB) announced that it will publish its first-quarter 2026 financial results on Tuesday, May 5, 2026, after the U.S. market close. The company specializes in next-generation technologies for biomedical research, focusing on mass cytometry and microfluidics to develop better medicines faster. Standard BioTools works with academic, government, pharmaceutical, and biotechnology laboratories worldwide.
Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
Standard BioTools Inc. (NASDAQ: LAB) announced that it will publish its first quarter 2026 financial results on Tuesday, May 5, 2026, after the U.S. market close. The company specializes in next-generation technologies that aid biomedical researchers and provides reliable insights in health and disease through its proprietary mass cytometry and microfluidics technologies. Standard BioTools collaborates with academic, government, pharmaceutical, and biotechnology laboratories worldwide.
May 5 after the bell: Standard BioTools to release Q1 numbers
Standard BioTools (NASDAQ: LAB) announced it will release its first-quarter 2026 financial results on May 5, 2026, after the U.S. market closes. Historically, similar announcements have caused only modest stock price movements. Investors will be looking to compare Q1 results against previous guidance and updates on the company's restructuring efforts.
Standard BioTools (LAB) is One of the Best Life Sciences Penny Stocks, Here is Why
Standard BioTools Inc. (NASDAQ:LAB) is highlighted as one of the top life sciences penny stocks, with analysts projecting a significant upside potential of over 52%. Despite Ark Invest reducing its holdings, the company's President & CEO, Michael Egholm, noted a successful past year with efficient processes and approximately $40 million in cost synergies. Standard BioTools specializes in providing consumables, instruments, and services for advanced molecular and proteomics analysis to biomedical researchers and scientists.
Standard BioTools (LAB) CEO reports RSU vesting, stock grants and options
Standard BioTools Inc. CEO Michael Egholm reported equity compensation activities, including the vesting of 196,513 restricted stock units (RSUs) into common shares and the withholding of 95,014 shares to cover tax obligations. He also received a grant of 2,345,340 stock options and an award of 1,042,373 shares of common stock, both vesting over four years. Following these transactions, Egholm directly holds 6,695,582 common shares and 2,345,340 stock options.
Equity awards expand holdings of Standard BioTools (LAB) senior executive
Standard BioTools (LAB) SVP & Chief Business Officer Sean Mackay received equity awards, including options to buy 612,240 shares at $0.9846 and 272,107 restricted stock units (RSUs). These awards, part of his compensation, vest over four years, with initial vesting in May 2026, contingent on his continued service. Following these grants, Mackay directly holds 1,032,281 shares of common stock.
Standard BioTools (NASDAQ: LAB) CFO equity awards and tax share withholding
Standard BioTools (NASDAQ: LAB) Chief Financial Officer Hanjoon Alex Kim reported routine equity compensation, including receiving 323,173 shares of common stock and a stock option for 727,140 shares. Additionally, 70,183 restricted stock units converted into common shares, with 21,301 shares withheld for tax obligations from a prior RSU grant. After these transactions, Kim directly held 2,779,401 common shares.
LAB SEC Filings - STANDARD BIOTOOLS INC 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Standard BioTools Inc.'s (NASDAQ: LAB) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It details recent material events such as the SomaScan business divestiture to Illumina, equity incentive plan updates, and executive compensation awards. The platform offers AI-powered summaries to help investors quickly digest key information from these regulatory disclosures.
Standard BioTools Inc (LAB) Stock Price Quote Today & Current Price Chart
This article provides the current stock price quote and chart for Standard BioTools Inc (LAB), emphasizing that Capital.com is a smart investment app for online trading.
Standard BioTools Inc (LAB) Stock Price Quote Today & Current Price Chart
This article provides a real-time stock price quote and current price chart for Standard BioTools Inc (LAB). It also references online trading via Capital.com.
Short Interest in Standard BioTools Inc. (NASDAQ:LAB) Declines By 18.5%
Short interest in Standard BioTools Inc. (NASDAQ:LAB) decreased by 18.5% in March, totaling 8,281,198 shares as of March 13th. Institutional investors now own about 53.74% of the stock, with several large investors increasing their stakes. The company recently beat revenue and EPS estimates but remains unprofitable, with analysts holding a consensus "Reduce" rating and a target price of $1.35.
Standard BioTools (NASDAQ:LAB) Stock Rating Upgraded by Wall Street Zen
Standard BioTools (NASDAQ:LAB) has been upgraded by Wall Street Zen from a "sell" to a "hold" rating, although the consensus among analysts remains "Reduce" with a target price of $1.35. The company recently exceeded earnings estimates, reporting $0.05 EPS against an expected ($0.03) and $23.8M in revenue versus $18.5M, but it continues to be unprofitable with a negative net margin. Institutional investors hold a significant portion of the stock, with some increasing their positions.
Long Focus Capital Management LLC Acquires 1,292,804 Shares of Standard BioTools Inc. $LAB
Long Focus Capital Management LLC increased its stake in Standard BioTools Inc. (NASDAQ:LAB) by 12.8% in the third quarter, acquiring an additional 1,292,804 shares. The firm now holds 11,362,804 shares, representing approximately 2.95% of the company, valued at $14.77 million. Despite beating quarterly earnings estimates with $0.05 EPS and $23.8 million in revenue, Standard BioTools remains unprofitable with a negative return on equity and net margin, leading analysts to a "Reduce" rating with a target price of $1.35.
Standard BioTools Inc. $LAB Shares Purchased by Mak Capital One LLC
Mak Capital One LLC significantly increased its stake in Standard BioTools (NASDAQ:LAB) by 184.6% in the third quarter of 2025, now holding 15,931,806 shares valued at approximately $20.7 million. Despite beating earnings and revenue estimates for the last quarter, Standard BioTools remains unprofitable and carries a consensus "Reduce" rating from analysts with an average price target of $1.35. The stock currently trades near $0.96.
Standard BioTools 2025 10-K: Revenue $85.3M, EPS $(0.20)
Standard BioTools reported 2025 revenue of $85.3 million, a 6% decline year-over-year, and an improved net loss per share of $(0.20). The company's strategic actions included consolidating R&D, relocating its headquarters, reducing its workforce, and divesting the SomaScan business to focus on mass cytometry and microfluidics. Despite a revenue decrease, operating losses narrowed due to reduced expenses.
Standard BioTools Inc. $LAB Stake Boosted by Casdin Capital LLC
Casdin Capital LLC increased its stake in Standard BioTools Inc. (NASDAQ:LAB) by 1.9% in the third quarter of 2026, making LAB its fourth-largest holding. Despite this significant institutional investment, Wall Street analysts have a "Reduce" consensus rating for Standard BioTools, with a target price of $1.35. The company reported better-than-expected EPS and revenue last quarter but remains unprofitable, with institutional investors owning 53.74% of the stock.
Standard BioTools (NASDAQ:LAB) Cut to "Sell" at Wall Street Zen
Wall Street Zen has downgraded Standard BioTools (NASDAQ:LAB) from a "hold" to a "sell" rating. The company, despite beating recent earnings and revenue estimates, remains unprofitable with a negative net margin. Analysts anticipate a negative EPS for the current year, and institutional investors have recently adjusted their holdings in LAB.
AI Investing Insights - Official Homepage - Intellectia AI™
This page provides news and event updates for LAB (Standard BioTools) stock, including its Q4 2025 earnings report, full-year 2025 revenue projections, and the completed sale of SomaLogic to Illumina. Standard BioTools reported strong Q4 revenue, exceeding expectations, and provided revenue guidance for fiscal year 2026. The company also highlighted its strengthened financial position and strategic flexibility following the SomaLogic sale.
Director at Standard BioTools (LAB) takes RSUs instead of cash pay
Troy Cox, a director at Standard BioTools (LAB), reported receiving 57,264 restricted stock units (RSUs) valued at $1.17 per share, instead of $67,000 in cash compensation for his board services. These RSUs increase his direct stake to 376,586 shares and will vest in four equal installments throughout 2026, conditional on his continued board service. This move aligns his compensation more closely with shareholder interests through equity incentives.
STANDARD BIOTOOLS (LAB) director takes 51,282 RSUs in lieu of $60K cash
Thomas D. Carey, a director at STANDARD BIOTOOLS INC. (LAB), has reported the acquisition of 51,282 Restricted Stock Units (RSUs) valued at $1.17 per share. These RSUs were accepted in place of $60,000 in cash compensation for his board service and will vest in four equal quarterly installments throughout 2026, contingent on his continued service. Following this transaction, Carey directly holds a total of 245,340 shares of common stock in the company.
Eli Casdin boosts equity stake in STANDARD BIOTOOLS (LAB) with 52,991 RSUs
Eli Casdin, a director and 10% owner of STANDARD BIOTOOLS (LAB), has increased his equity stake by receiving 52,991 restricted stock units (RSUs) valued at $1.17 per share. These RSUs were accepted in lieu of $62,000 in cash compensation for his board service and will vest in four equal installments throughout 2026, contingent on his continued board membership. Following this transaction, Casdin directly holds over 2.95 million common shares, with additional indirect holdings through various investment funds he is associated with.
LAB Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of STANDARD BIOTOOLS INC (LAB), detailing its income statement, balance sheet, cash flow, and key financial ratios through fiscal year 2024, derived from SEC filings. It highlights the company's rapid revenue growth (64% YoY) but also significant unprofitability, negative operating and free cash flow, and low earnings quality. The analysis includes financial health scores, Piotroski F-Score, and interest coverage, indicating moderate overall financial health with concerns regarding profitability and cash generation.
Standard BioTools (NASDAQ:LAB) Upgraded to Hold at Wall Street Zen
Wall Street Zen has upgraded Standard BioTools (NASDAQ:LAB) from a "sell" to a "hold" rating, contributing to the stock's consensus "Reduce" rating with an average $1.35 price target. The company recently surpassed quarterly earnings and revenue expectations ($0.05 EPS vs. $-0.03 consensus; $23.8M revenue vs. $18.5M), despite remaining unprofitable with a negative return on equity and net margin. Insider activity shows significant buying, with Casdin Partners purchasing 150,000 shares and total insider acquisitions reaching 350,000 shares in the last three months, bringing insider ownership to 23.16%.
Standard BioTools (LAB) SVP disposes shares for tax withholding
Sean Mackay, SVP & Chief Business Officer of Standard BioTools Inc. (LAB), reported a tax-related share disposition on February 23, 2026. A total of 19,661 shares of common stock were withheld to cover tax obligations from previously vested restricted stock units, at a price of $1.15 per share. After this transaction, Mackay directly holds 760,174 shares of Standard BioTools common stock.
Standard BioTools Inc. (LAB) Stock Analysis: Unveiling a 32% Upside Potential Amidst Challenging Metrics
Standard BioTools Inc. (LAB) shows a potential 32.48% upside despite significant financial challenges, including declining revenue, negative EPS, and cash flow issues. The company, formerly Fluidigm Corporation, is innovating in proteomics and genomics, supported by academic partnerships. Analysts maintain a cautious but positive outlook, with a target price suggesting potential growth for risk-tolerant, long-term investors.
Standard BioTools (LAB) Q4 Profit Challenges Longstanding Unprofitable Narrative
Standard BioTools (LAB) reported a mixed set of FY 2025 numbers, with a Q4 profit of US$0.04 EPS, a notable improvement against its full-year loss. While bears point to the company's 5.3x P/S multiple despite ongoing losses and forecasted unprofitability, bulls see the Q4 profit as a potential early sign of improved margins due to cost synergies. The company's DCF fair value of US$4.37 contrasts sharply with its current US$1.17 share price, creating tension between valuation models and the company's current operating trends.
